Literature DB >> 29016821

Super-response to cardiac resynchronization therapy reduces appropriate implantable cardioverter defibrillator therapy.

Ammar M Killu1, Anna Mazo2, Avishay Grupper2, Malini Madhavan1, Tracy Webster1, Kelly L Brooke1, David O Hodge3, Samuel J Asirvatham1, Paul A Friedman1, Michael Glikson2, Yong-Mei Cha1.   

Abstract

Aims: To determine the frequency of implantable cardioverter defibrillator (ICD) therapy following cardiac resynchronization therapy (CRT-D) implantation in super and non-super responders and whether greater improvement in left ventricular (LV) function after CRT is associated with a reduced burden in ICD therapy. Methods and results: This is a two-centre, retrospective study between January 2002 and September 2011. Patients were classified as non-super responders and super-responders based on the post-CRT ejection fraction (EF) of < 50% and ≥50%, respectively. Of 629 recipients of CRT-D, 37 (5.9%) were super-responders. Implantable cardioverter defibrillator follow-up was available for a mean duration of 6.2 ± 2.7 years. The 5-year rate of antitachycardia pacing (ATP) in super-responders was significantly lower than in non-super responders (2.7% vs. 22.1%, P = 0.004). Super-responders also had a lower 5-year rate of appropriate ICD shock compared with non-super responders (2.7% vs. 14.3%, P = 0.03). On multivariable analysis, factors associated with appropriate ICD therapy (ICD shock/ATP) include male gender (hazard ratio, HR 1.97, 95% confidence interval, 95% CI 1.15-3.35), secondary prevention indication (HR 2.09, 95% CI 1.13-3.85), increased baseline LV end-systolic diameter (HR 1.03 per mm, 95% CI 1.01-1.06) and higher baseline EF (HR 1.03 per %, 95% CI 1.00-1.06) while super-responder status was highly protective (HR 0.13, 95% CI 0.02-0.91).
Conclusion: Recipients of CRT-D that normalize their EF have very low rates of ventricular arrhythmias requiring appropriate ICD therapy compared with those that do not.

Entities:  

Mesh:

Year:  2018        PMID: 29016821     DOI: 10.1093/europace/eux235

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  4 in total

1.  Heart Failure Duration Combined with Left Atrial Dimension Predicts Super-Response and Long-Term Prognosis in Patients with Cardiac Resynchronization Therapy Implantation.

Authors:  Zhinian Guo; Xiaoyan Liu; Chuan Liu; Jie Yang; Xiaofeng Cheng; Yunlong Chen; Ping Li; Yongming He; Jiang Wang
Journal:  Biomed Res Int       Date:  2019-06-24       Impact factor: 3.411

2.  Non-transmural myocardial infarction associated with regional contractile function is an independent predictor of positive outcome: an integrated approach to myocardial viability.

Authors:  Gianluca Di Bella; Giovanni Donato Aquaro; Jan Bogaert; Paolo Piaggi; Antonio Micari; Fausto Pizzino; Giovanni Camastra; Scipione Carerj; Mariapaola Campisi; Antonio Bracco; Maria Ludovica Carerj; Michele Emdin; Bijoy K Khandheria; Alessandro Pingitore
Journal:  J Cardiovasc Magn Reson       Date:  2021-11-01       Impact factor: 5.364

3.  Cardiac electrical and mechanical synchrony of super-responders to cardiac resynchronization therapy.

Authors:  Ke-Bei Li; Zhi-Yong Qian; Xue-Song Qian; Yong Zhou; Di-Di Zhu; Yuan-Hao Qiu; Yao Wang; Xiao-Feng Hou; Jian-Gang Zou; Yu-Feng Sheng
Journal:  Chin Med J (Engl)       Date:  2020-01-20       Impact factor: 2.628

4.  The effect of iron deficiency on cardiac resynchronization therapy: results from the RIDE-CRT Study.

Authors:  Philipp Lacour; Phi Long Dang; Daniel Armando Morris; Abdul Shokor Parwani; Wolfram Doehner; Franziska Schuessler; Felix Hohendanner; Frank R Heinzel; Andrea Stroux; Carsten Tschoepe; Wilhelm Haverkamp; Leif-Hendrik Boldt; Burkert Pieske; Florian Blaschke
Journal:  ESC Heart Fail       Date:  2020-03-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.